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Propylthiouracil (PTU) and methimazole (MMI) are the most commonly used antithyroid drugs. The available data suggest that
these drugs may block the thyroid hormone synthesis by inhibiting the thyroid peroxidase (TPO) or diverting oxidized iodides
away from thyroglobulin. It is also known that PTU inhibits the selenocysteine-containing enzyme ID-1 by reacting with the se-
lenenyl iodide intermediate (E-SeI). In view of the current interest in antithyroid drugs, we have recently carried out biomimetic
studies to understand the mechanism by which the antithyroid drugs inhibit the thyroid hormone synthesis and found that the
replacement of sulfur with selenium in MMI leads to an interesting compound that may reversibly block the thyroid hormone
synthesis. Our recent results on the inhibition of lactoperoxidase (LPO)-catalyzed oxidation and iodination reactions by antithy-
roid drugs are described.
Copyright © 2006 G. Roy and G. Mugesh. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
INTRODUCTION
Thyroxine or 3,3 ,5,5 -tetraiodothyronine (T4) is the major
hormone secreted by the follicular cells of the thyroid gland.
This hormone is produced on thyroglobulin by thyroid per-
oxidase (TPO)/hydrogen peroxide/iodide system. The syn-
thesis of T4 by TPO involves two independent steps: iod-
ination of tyrosine and phenolic coupling of the resulting
iodotyrosine residues [1–5]. The prohormone T4 is then
converted to its biologically active form T3 by an outer ring
deiodination pathway. This particular reaction is catalyzed
by a selenocysteine-containing enzyme called iodothyronine
deiodinase (ID-I), which is present in highest amounts in
liver, kidney, thyroid, and pituitary [6–16]. The thyroid gland
also produces an inactive metabolite rT3 by an inner ring
deiodination pathway. The triiodo derivatives T3 and rT3
are further metabolized by inner ring and outer ring deio-
dination, respectively, by ID-I, ID-II, and ID-III to produce
the inactive metaboilite T2 (3,3 - T2, 3,5- T2, and 3 ,5 - T2).
The outer ring 5 -deiodination catalyzed by the ID-I enzyme
is considered to be the first step in thyroid hormone ac-
tion because this is the only deiodination pathway that leads
to the formation of an active thyroid hormone. It is now
widely accepted that the deiodination catalyzed by ID-I is
a ping-pong, bisubstrate reaction in which the selenol (or
selenolate) group of the enzyme (E-SeH or E-Se) first re-
acts with thyroxine (T4) to form a selenenyl iodide (E-SeI)
intermediate. Subsequent reaction of the selenenyl iodide in-
termediate with an as yet unidentified intracellular cofactor
completes the catalytic cycle and regenerates the enzyme ac-
tive site (Figure 1) [8, 14]. Although it is customary to use
dithiothreitol (DTT, 1,4-dithiothreitol, Cleland’s reagent) as
the second substrate in in vitro experiments, the identity
of the physiological second substrate is still uncertain. The
tripeptide glutathione (GSH) can also act as a thiol cosub-
strate, but GSH is a much less potent cofactor than DTT for
ID-I [10, 17]. In addition to GSH, other native thiols such as
dihydrolipoic acid or dihydrolipoamide may serve as cofac-
tors for ID-I [17, 18]. Therefore, Figure 1 may be an incom-
plete or incorrect representation of the catalytic mechanism
of ID-I since evidence for the cofactor systems mentioned
above has only been presented for in vitro studies and not
for in vivo analysis.
Although the deiodination reactions are essential for the
function of thyroid gland, the activation of thyroid stimu-
lating hormone (TSH) receptor by autoantibodies leads to
an overproduction of thyroid hormones. As these antibod-
ies are not under pituitary feedback control system, there
is no negative influence on the thyroid activity and, there-
fore, the uncontrolled production of thyroid hormones leads
2 Bioinorganic Chemistry and Applications
HO
I
I I
IO
H
CO2H
NH2
T4
HO I
I I
O
H
CO2H
NH2
T3
E  Se  Au
GTG
E  Se H+ E  SeI
PTU
HI
E  Se  S
OH
N
N
CH2CH2CH3
DTTox HO
HO
S
S
HI
OH
SHHS
OH
DTTred
Figure 1: Proposed mechanism for the deiodination of thyroxine by ID-I and inhibition of ID-I by n-propyl-2-thiouracil (PTU) and gold
thioglucose (GTG).
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Figure 2: Chemical structures of some commonly employed an-
tithyroid drugs and their selenium analogues.
to a condition called “hyperthyroidism.” The overproduc-
tion of T4 and T3 can be controlled by blocking the thyroid
hormone biosynthesis or reducing the conversion of T4 to
T3. The thiourea drugs such as methimazole (1, MMI), 6-n-
propyl-2-thiouracil (3, PTU), and 6-methyl-2-thiouracil (5,
MTU) are generally employed for this purpose (Figure 2).
Despite the importance of these antithyroid drugs in the
treatment of hyperthyroidism, the detailed mechanism of
their action is still not clear. According to the initially pro-
posed mechanism, these drugs may divert oxidized iodides
away from thyroglobulin by forming stable electron donor-
acceptor complexes with diiodine, which can effectively re-
duce the thyroid hormone biosynthesis [19, 20]. It has also
been proposed that these drugs may block the thyroid hor-
mone synthesis by coordinating to themetal center of thyroid
peroxidase (TPO) [21]. After the discovery that the ID-I is
responsible for the activation of thyroxine, it has been re-
ported that PTU, but not MMI, reacts with the selenenyl io-
dide intermediate (E-SeI) of ID-I to form a selenenyl sulfide
as a dead end product, thereby blocking the conversion of
T4 to T3 during the monodeiodination reaction (Figure 1)
[8, 14, 22–24]. The mechanism of antithyroid activity is fur-
ther complicated by the fact that the gold-containing drugs
such as gold thioglucose (GTG) inhibits the deiodinases by
reacting with the selenol (or selenolate) group of the native
enzyme (Figure 1) [8, 24].
In recent years, the selenium analogues 2 (MSeI), 4
(PSeU), and 6 (MSeU) attracted considerable attention be-
cause these compounds are expected to be more nucle-
ophilic than their sulfur analogues and the formation of an
 Se Se  bond may occur more readily than the formation
of an  Se S  bond with the ID-I enzyme [25–29]. How-
ever, the data derived from the inhibition of TPO by sele-
nium compounds show that these compounds may inhibit
the TPO activity by a different mechanism. We have recently
shown that the unexpected behavior of the selenium com-
pound MSeI as compared to that of its sulfur analogue may
be due to the existence of this compound in the zwitterionic
form and its facile oxidation to the corresponding diselenide
(8) [30, 31]. In this paper, we summarize our recent results
on the effect of antithyroid drugs on peroxide-catalyzed ox-
idation and iodination reactions. In addition, we show that
the replacement of sulfur with selenium in MMI leads to an
interesting compound (MSeI) that exhibits significant glu-
tathione peroxidase (GPx)-like antioxidant activity.
INHIBITION OF LACTOPEROXIDASE-CATALYZED
OXIDATION BY ANTITHYROID DRUGS
The effect of antithyroid drugs on peroxidase-catalyzed
oxidation was studied in vitro by using spectroscopic
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Table 1: Inhibition of LPO activity by 1–3, and 5 [31].
No Compound IC50 (μM)a
1 MMI (1) 7.0  1.1
2 MSeI (2) 16.4  1.5
3 PTU (3) 45.0  2.1
4 MTU (5) 47.8  0.1
a Concentration of the compound causing 50% inhibition. Each IC50 value
was calculated from at least three independent experiments.
techniques. The enzyme inhibition experiments were car-
ried out with iron-containing lactoperoxidase (LPO) since it
is readily available in purified form. Furthermore, LPO has
been shown to behave very similarly to TPO with respect to
oxidation of organic substrates and iodination of thyroglob-
ulin and other iodide acceptors [32]. We have employed 2,2 -
azio-bis-3-ethyl-benthiazoline-6-sulfonic acid (ABTS) and
H2O2 as substrates [33] to determine the half-maximal in-
hibitory concentration (IC50) of test compounds. The IC50
values for the inhibition of LPO-catalyzed oxidation of ABTS
by 1–3 and 5 are summarized in Table 1 [31]. The sulfur
compound MMI inhibited the LPO activity with an IC50
value of 7.0  1.1 μM, which is much lower than those ob-
served with PTU and MTU. The selenium analogue (2) also
inhibited LPO activity and the IC50 value was found to be
almost 2-3 times lower than those of PTU and MTU. The
higher activity of MMI as compared with those of PTU and
MTU is in agreement with the previous studies on the in-
hibition of TPO. Since the activation of the iron center in
TPO must proceed through an interaction of Fe(III) with
H2O2, TPO inactivation may occur through a competitive
coordination of the drug to iron, assisted by hydrogen bond-
ing with a histidine residue of the TPO enzyme [34]. Un-
der these conditions, MMI might compete more successfully
than PTU with H2O2 because the hydrogen-bond (hard) ba-
sicity pkHB value of MMI (2.11) is much higher than that of
PTU (∼ 1.32). Similarly to PTU, the methyl derivative 5 is
also expected to be a weak inhibitor of TPO. On the other
hand, compound 2, which exists predominantly in the zwit-
terionic form (Scheme 1) [35], probably does not have the
ability to coordinate to the iron center; therefore, this com-
pound may inhibit the LPO activity by a different mecha-
nism. Although the zwitterionic selenolate can be oxidized
in solution to give the corresponding diselenide (8), the ob-
served inhibitory activity must be ascribed entirely to the
presence of the reduced form (2) as the oxidized compound
(8) does not show any noticeable inhibition behavior under
identical experimental conditions.
Taurog et al have shown that MMI and related deriva-
tives irreversibly inhibit LPO and TPO, leading to a com-
plete inactivation of the enzymes [36–39]. Doerge and others
have shown that mammalian peroxidases including LPOmay
activate the antithyroid drugs through S-oxygenation to pro-
duce the corresponding sulfoxides or sulfinic acids [40, 41].
They have also shown that the suicide inactivation of LPO
and TPO byMMI proceeds through the S-oxygenation of the
thione moiety to form a reactive sulfinic acid, which binds
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Scheme 1: The possible tautomeric structures of compound 2. The
compound exists predominantly in its zwitterionic form 2c, which
may have a partial CSe double bond character.
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Figure 3: Plot of initial rates (vo) for the LPO-catalyzed oxidation of
ABTS versus concentration of H2O2: (a) control activity; (b) 40 μM
of 2; (c) 40 μMof 8; (d) 80 μMof PTU; (e) 80 μMofMTU; (f) 40 μM
of MMI. Conditions: LPO: 6.5 nM; H2O2: 22.9 μM (see [31]).
covalently to the prosthetic heme and irreversibly blocks en-
zyme activity [42–45]. Given the higher reactivity of sele-
nium compounds as compared with the sulfur derivatives
toward oxidation, it is possible that the facile oxidation of
the selenium compounds may lead to an efficient inhibition
of LPO activity. With this in mind, we treated MMI, PTU,
MTU, and MSeI with H2O2 before adding LPO and ABTS.
The LPO activity was measured several times by increasing
the time for the reaction of the test compounds with H2O2.
Remarkably, MSeI (2) inhibited the enzyme within few sec-
onds even at lower concentrations, which can be ascribed
to the facile oxidation of the reactive selenolate group in 2
(MSeI) by H2O2 or by the oxidized enzyme. Because MMI
also inhibits the enzyme very efficiently, we have carried out
further experiments to prove that the mechanisms by which
MMI and MSeI exert their inhibitory action are different.
The initial rates (v0) derived from various concentrations of
H2O2 were plotted against the concentration of H2O2. The
LPO activity was completely inhibited by 40 μM MMI, and
the enzyme’s activity could not be recovered by increasing
the H2O2 concentration (Figure 3f) [31]. The LPO activity
could not be recovered even at lower concentration of MMI
(10 μM) and higher concentration of H2O2 (230 μM). This
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suggests that MMI does not act on H2O2 but acts on the en-
zyme itself, leading to an irreversible inhibition as previously
proposed. On the other hand, 2 also inhibited the LPO activ-
ity as efficiently as MMI, but in this case, the enzyme’s activ-
ity could be completely recovered by increasing H2O2 con-
centration (Figure 3b). These observations may support the
assumption that MSeI, in contrast to MMI, does not inter-
fere with the native enzyme directly but it inhibits the LPO
activity by reducing the H2O2, which is required for the oxi-
dation of the iron center in LPO. The reduction of H2O2 by 2
may become more efficient in the presence of suitable thiols
such as GSH because this process may constitute a redox cy-
cle involving a catalytic reduction of H2O2 (glutathione per-
oxidase (GPx) activity) [46]. Thus, compound 2 mimics the
action of GPx, a selenoenzyme that protects the cellular com-
ponents from oxidative damage by reducing H2O2 with the
help of GSH [16]. Recently, the GPx enzyme present in thy-
roid gland has been shown to inhibit the iodination reactions
by degrading the intracellular H2O2 [47, 48]. The high GPx
activity of the key compound 2 leads to an assumption that
the antithyroid drugs may act as antioxidants in addition to
their inhibition behavior.
INHIBITION OF LACTOPEROXIDASE-CATALYZED
IODINATION BY ANTITHYROID DRUGS
The interesting results that we obtained from the inhibition
of LPO-catalyzed oxidation reactions by MSeI (2) prompted
us to study the effect of this compound and related deriva-
tives on the LPO-catalyzed iodination reactions [49]. In ad-
dition, we have studied the reactivity of MSeI toward iodine
because the effect of the selenium compounds on the io-
dination of tyrosine and the identification of the products
formed in the reactions of these compounds with iodine are
crucial in understanding the mechanism of action in vivo of
these drugs. The iodination of tyrosine was studied by using
LPO/H2O2/I assay and the initial rates for the conversion of
L-tyrosine to 3-iodo L-tyrosine (Scheme 2) were determined
by an HPLC method.
As the formation of 3,5-diiodo-L-tyrosine was also ob-
served in the reaction, only the initial 5%–10% of the con-
version was followed where only a trace amount of the di-
iodo compound was produced. The decrease in the concen-
tration of L-tyrosine was followed by measuring the peak
area at 277 nm and the amount of tyrosine present in the so-
lution at a given time was calculated from the calibration plot
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Figure 4: Inhibition of the LPO-catalyzed iodination of L-tyrosine
by MSeI. The decrease in the amount of tyrosine with time was fol-
lowed by HPLC: (a) control; (b) 6 μM of 2; (c) 9 μM of 2; (d) 12 μM
of 2; (d) 15 μM of 2; and (e) 20 μM of 2 (see [49]).
obtained by injecting known concentrations of L-tyrosine.
The effect of compound 2 on the iodination reaction was de-
termined at various concentrations of 2 under identical ex-
perimental conditions (Figure 4). The incubation mixtures
for the HPLC analysis contained KI, L-tyrosine, hydrogen
peroxide, and LPO enzyme. The mixture was incubated in
phosphate buffer at room temperature and aliquots were in-
jected onto the HPLC column and eluted with gradient sol-
vent system (0.1% TFA in water-MeCN). The decrease in
the amount of tyrosine (μg) was calculated from the cali-
bration plot. The concentration of compound 2 was varied
from 6 μM to 20 μM, and a significant inhibition was ob-
served even at the lowest concentration of 2.
To understand the effect of peroxide substrate on the re-
action rate and the inhibition, the LPO activity was deter-
mined at various concentrations of hydrogen peroxide. In
addition, the effect of peroxide on the inhibition of LPO-
catalyzed iodination by antithyroid drugs 1 and 2 was eval-
uated by carrying out the experiments at various concentra-
tions of H2O2. In this HPLC assay, the incubation mixtures
containing KI, L-tyrosine, LPO enzyme, and various concen-
trations of hydrogen peroxide were incubated at room tem-
perature. The aliquots were removed from the reaction mix-
ture at various time intervals, injected onto the HPLC col-
umn and eluted with gradient solvent system (0.1% TFA in
water-MeCN). The formation of monoiodo tyrosine was fol-
lowed at 295 nm. The initial rates (v0) derived for various
concentrations of H2O2 were plotted against the concentra-
tion of H2O2. Although the LPO activity was inhibited by 2
at lower concentrations of H2O2, the enzyme’s activity could
be completely recovered by increasing H2O2 concentration
(Figure 5). These results suggest that the concentration of
H2O2 has a dramatic effect on the inhibition of iodination
reaction by compound 2 (Figure 5) [49].
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Figure 5: Inhibition of the LPO-catalyzed iodination of L-tyrosine
byMSeI. Effect of H2O2 on the inhibition by 2; (a) 0 μM; (b) 20 μM;
(c) 30 μM; (d) 40 μM; inset: inhibition of tyrosine iodination by (e)
1; (f) 2 at a fixed H2O2 concentration.
The IC50 values for the inhibition of LPO-catalyzed
iodination of L-tyrosine by the test compounds were also
determined by following the same procedure. The initial
rates for the iodination reaction were determined at various
concentrations of inhibitors. The inhibition curves obtained
by plotting the percentage control activity against the con-
centration of inhibitors are shown in Figure 5 (inset). As ex-
pected, MMI exhibited a strong inhibition with an IC50 value
of 5.2 μM, which is comparable with the IC50 value obtained
for the LPO-catalyzed oxidation reaction [30, 31]. The sele-
nium analogue (2) also showed a strong inhibition with an
IC50 value of 12.4 μM, which is consistent with the effect of
this compound on peroxidase-catalyzed oxidation reactions
[30, 31]. Similarly to the LPO-catalyzed oxidation of 2,2 -
azino-bis-3-ethylbenz-thiazoline sulfonic acid (ABTS), this
suggests that the selenium analogue may inhibit the LPO by
a different mechanism. The diselenide 8, on the other hand,
did not show any noticeable inhibition under identical con-
ditions. This confirms that the reduction of the diselenide to
the corresponding selenolate is essential for an efficient inhi-
bition of LPO-catalyzed oxidation or iodination reactions.
INTERACTION OF ANTITHYROID DRUGS WITH IODINE
The nature of charge-transfer complexes between hetero-
cyclic antithyroid drugs and diiodine is an important area of
interest in the study of hyperthyroidism [50], and the elec-
trical properties in general and the superconducting ability,
in particular, of sulfur-iodine complexes are also of current
interest [51–54]. Recently, a great deal of effort has been de-
voted to the understanding of the interaction of antithyroid
drugs with iodine [55–59]. These studies may provide insight
into the nature of products formed during the inhibition
of thyroid hormone synthesis. As mentioned in the intro-
duction, it has been proposed that these drugs may divert
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Figure 6: Chemical structures of compounds 9 and 10 derived from
the compound 2.
oxidized iodides away from thyroglobulin by forming stable
electron donor-acceptor complexes with diiodine, which can
effectively reduce the thyroid hormone biosynthesis [19, 20].
Because the oxidation of MMI to the corresponding disulfide
(7) by TPO/H2O2/I system is associated with the reaction of
MMI with I2 [55–59], we have investigated the interaction of
2 and 8 with iodine. It has been reported that I2 chemically
oxidizes MMI to produce ionic disulfides that exist in two
different protonated forms [55]. It is unknown whether the
selenium analogue of MMI, in its reduced form, also under-
goes such oxidation by I2 to produce ionic species (Figure 6).
Therefore, we carried out the experiments with the reduced
species (2), which exists in its zwitterionic form [31, 35]. The
reaction of 2 with I2 in CH2Cl2 produced red-brown crystals.
Interestingly, the X-ray crystal structure shows the formation
of compound 9, which consists of a monocation containing
a diselenide and I3
 as counterion (Figure 7) [49]. This is in
contrast to the reaction of MMI with I2 in CH2Cl2, which af-
forded a disulfide-containing dication and I8
 as counterions
[55].
The formation of the monocationic species 9 is inter-
esting from a chemical point of view as only one of the
imidazole rings undergoes oxidation. It should be men-
tioned that the N-methylation on MMI has been shown
to abolish its TPO inhibitory activity [60]. Freeman et al
have shown that the reaction of the N-methylated derivative
(1,3-dimethylimidazole-2-thione) with I2 does not produce
any disulfide, but it produces a 1 : 1 thione : I2 charge-
transfer adduct [61]. The N-methylated derivative of 2 (1,3-
dimethylimidazole-2-selone), on the other hand, produces a
hypervalent “T-shaped” compound having I Se I moiety
[62, 63]. It should be noted that the reaction of the methy-
lated analogue of 2, 1,3-dimethylimidazole-2-selone, with
one equivalent bromine affords a hypervalent compound
having Br Se Br moiety, whereas the corresponding reac-
tion utilizing a half-equivalent bromine leads to the forma-
tion of a diselenide dication having two Br as counterions
[64]. Therefore, the existence of 2 in its zwitterionic (or se-
lenolate) form is probably responsible for its different reac-
tivity toward iodine. Stable open-chain cationic diselenide
species are very uncommon in the literature and to the best
of our knowledge no structural information is available for
complexes derived from the reactions of selenium analogues
of antithyroid drugs with iodine. The chemical oxidation of 2
by I2 suggests that compound 8, which exists in the oxidized
form of 2, may not produce any ionic species. To test this,
the diselenide 8 was treated with I2 in a 1 : 2 molar ratio in
CH2Cl2.
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Figure 7: Molecular structures of (a) monocation 9 showing the
hydrogen bonding between two monocations and (b) dication 10
[49].
This reaction yielded a brown solution from which dark-
brown crystals were obtained on standing at room tempera-
ture. Surprisingly, the X-ray crystal structure shows the for-
mation of a monocationic species, which is identical with
that obtained from the reaction of 2 with I2 (Figure 7). The
formation of a cationic species in this reaction is quite un-
expected because the reactions of iodine with diselenides
generally produce selenenyl iodide species or charge-transfer
complexes having diselenide-molecular iodine adducts [65].
It is also known that some of the selenenyl iodides may
undergo disproportionation to give diselenide-iodine com-
plexes.
The far-IR spectrum of complex 9 shows a distinct band
at 135 cm1 for the ν(I I) stretching vibration mode. This
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Figure 8: FT-Raman spectra of the monocation 9 (a), diselenide 8
(b), and the dication 10 (c) (see [49]).
is in agreement with the fact that I2 gives a strong band at
180 cm1 in the solid state, which shifts to lower wavenum-
bers upon coordination to a donor atom, reflecting a re-
duction in the I I bond order [56]. The FT-Raman spec-
trum of the complex in the ν(I I) region shows intense
peaks at 164 cm1, 143 cm1, and 110 cm1. In addition, a
weak band is observed around 67 cm1 (Figure 8). The band
at 110 cm1 can be certainly assigned to the ν1 symmetric
stretching of I3
, which being a symmetrical ion normally ex-
hibits only one Raman active band. However, when a distor-
tion of I3
 occurs, the antisymmetric stretching may become
Raman active and additional bands at higher (140 cm1–
130 cm1) and at lower frequencies (80 cm1–70 cm1) may
be observed [56, 66]. Therefore, the relatively weak bands at
143 cm1 and 67 cm1 can be attributed to the antisymmet-
ric stretching and deformation motions, respectively, for the
I3
 ion (Figure 8a).
The single crystal X-ray studies confirm the proposed
structure of 9 (Figure 7), which consists of two independent
diselenidemonocations [Se Se: 2.382 A˚; 2.364 A˚]. These dis-
elenide cations interact with their symmetry equivalents
through N H  N hydrogen bonds to form dimeric units
with overall charge 2+. The charge balance in the crystals is
achieved by the presence of two I3
 anions. The two C Se
bond lengths in each subunit are unequal due to the mono-
protonation of the one of the five-membered rings [C Se:
1.886–1.890 A˚]. The I I bond lengths observed also differ
significantly from the corresponding I I bond length of I2
in the solid state (2.715 A˚). The two I I bond lengths of the
I3
 species in complex 9 range from 2.888 A˚ to 2.919 A˚, indi-
cating a slight distortion of the I3
 moiety. This distortion is
probably responsible for additional bands in the FT-Raman
spectrum of the complex.
In the reaction between 8 and I2 in dichloromethane,
the concentrations of I2 do not appear to change the na-
ture of products. During our attempts to oxidize the second
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ring using various concentrations of I2 up to an excess, only
the monocation was obtained as a stable product. However,
the choice of solvent has been found to have a large influ-
ence on the nature of products formed. The reaction of 8
with I2 in a 1 : 2 molar ratio in water produced a mixture
containing both monocation (9) and dication (10) as con-
firmed by single-crystal X-ray studies (Figure 7). In contrast
to the monocation, the charge balance in the crystal of dica-
tion is achieved by two I anions. In compound 10, the aver-
age C Se bond length of 1.895 A˚ is comparable with that of
the diselenide 8 (1.880 A˚) [30], but this is significantly longer
than the average C Se bond length (1.848 A˚) found in com-
pound 2 that exists in a zwitterionic form [35]. As expected,
the FT-Raman spectrum of compound 10 shows no peaks in
the region of lower wavenumbers (Figure 8c), indicating the
absence of any polyiodide species in the crystals.
CONCLUSION AND OUTLOOK
Our recent results show that the selenium analogue of methi-
mazole (MSeI) exists predominantly in its zwitterionic form,
in which the selenium atom carries a negative charge and
the five-membered heterocyclic ring carries a positive charge.
In contrast to the sulfur analogue, the zwitterionic form of
MSeI is unstable and oxidizes in air to the corresponding dis-
elenide. The resulting diselenide can be easily reduced by re-
ducing agents such as NaBH4 or glutathione (GSH). In its
reduced form (zwitterionic or selenolate), MSeI effectively
and reversibly inhibits the lactoperoxidase (LPO)-catalyzed
oxidation reactions. These results suggest that MSeI may not
interfere with the native enzyme directly, but it may inhibit
LPO either by reducing the H2O2 that is required for the ox-
idation of the iron center in LPO or by interfering with the
oxidized enzyme. In the presence of GSH, MSeI may con-
stitute a redox cycle involving a catalytic reduction of H2O2
and thereby mimics the glutathione peroxidase (GPx) activ-
ity in vitro. In addition, MSeI effectively inhibits the LPO-
catalyzed iodination of L-tyrosine and the inhibition could
be completely recovered by increasing the H2O2 concentra-
tion. These studies reveal that the degradation of the intracel-
lular H2O2 by the selenium analogues of antithyroid drugs
may be beneficial to the thyroid gland as these compounds
may act as antioxidants and protect thyroid cells from ox-
idative damage. In addition to its antioxidant activity, MSeI
reacts with I2 to produce novel ionic diselenides containing
iodide or polyiodide anions, which might be effective inter-
mediates in the inhibition of thyroid hormones. However,
further studies with TPO are required to derive some firm
conclusions regarding the mode of action of the antithyroid
drugs. Our future work will focus on the design and synthesis
of novel sulfur and selenium compounds and study of their
antithyroid and antioxidant activities.
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